The institution grant opens a trial phase; monitor for the final written decision (due ~12 months) and any related district-court or ITC litigation that may be stayed or affected.
Price Chart
Executive Summary
The PTAB granted institution of inter partes review in IPR2026-00374, allowing Merck (as petitioner Merck Sharp & Dohme LLC) to proceed with challenging claims of U.S. Patent 11058757 owned by Pogona, LLC. This is an interlocutory ruling — no claims have been cancelled, and a final written decision is expected within about a year.
PTAB Trial Details
Key Facts
- PTAB instituted IPR2026-00374 on October 21, 2026, finding a reasonable likelihood Merck would prevail on at least one challenged claim.
- Patent U.S. 11058757 covers 'Saccharide-polypeptide conjugate compositions and methods of use thereof'.
- Patent owner is Pogona, LLC; petitioner is Merck Sharp & Dohme LLC (a Merck & Co. subsidiary).
- This is an institution grant — an interlocutory decision; no claims have been invalidated.
Financial Impact
Not stated in the decision; no products or revenue exposure are mentioned.
Risk Factors
- A final written decision finding claims unpatentable could remove a patent obstacle for Merck, but the patent owner may appeal to the Federal Circuit.
- The patent's subject matter is not tied to any named Merck product in the decision, limiting near-term materiality.
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-IPR2026-00374-ins-MRK |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 3/A | $145.27 | awaiting T+20 | — | $140.61 (−3.21%) |
Oct 21, 2026 6d ago | PTAB Trial | $147.24 | awaiting T+20 | — | $140.61 (−4.50%) |
Oct 15, 2026 12d ago | PTAB Trial | $145.95 | awaiting T+20 | — | $140.61 (−3.66%) |
Oct 15, 2026 12d ago | PTAB Trial | $145.95 | awaiting T+20 | — | $140.61 (−3.66%) |
Oct 13, 2026 13d ago | 8-K | $141.98 | awaiting T+20 | — | $140.61 (−0.96%) |
Sep 29, 2026 28d ago | Court Ruling | $145.31 | awaiting T+20 | — | $140.61 (−3.23%) |
Sep 28, 2026 29d ago | Court Ruling | $149.28 | awaiting T+20 | — | $140.61 (−5.81%) |
Sep 22, 2026 5w ago | Court Ruling | $148.08 $149.88 | ▲ +1.22% | ▲ +0.53% | $140.61 (−5.04%) |
Sep 11, 2026 6w ago | Court Ruling | $144.85 $145.45 | ▲ +0.41% | ▼ −1.85% | $140.61 (−2.93%) |
Sep 9, 2026 6w ago | Court Ruling | $144.71 $142.38 | ▼ −1.61% | ▼ −3.73% | $140.61 (−2.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers